| Literature DB >> 33813279 |
Nontaphat Leerach1, Seiichi Munesue1, Ai Harashima1, Kumi Kimura1, Yu Oshima1, Shuhei Kawano1, Mariko Tanaka1, Akane Niimura1, Natthiya Sakulsak2, Hiroshi Yamamoto3, Osamu Hori4, Yasuhiko Yamamoto5.
Abstract
The engagement of the receptor for advanced glycation end-products (receptor for AGEs, RAGE) with diverse ligands could elicit chronic vascular inflammation, such as atherosclerosis. Binding of cytoplasmic tail RAGE (ctRAGE) to diaphanous-related formin 1 (Diaph1) is known to yield RAGE intracellular signal transduction and subsequent cellular responses. However, the effectiveness of an inhibitor of the ctRAGE/Diaph1 interaction in attenuating the development of atherosclerosis is unclear. In this study, using macrophages from Ager+/+ and Ager-/- mice, we validated the effects of an inhibitor on AGEs-RAGE-induced foam cell formation. The inhibitor significantly suppressed AGEs-RAGE-evoked Rac1 activity, cell invasion, and uptake of oxidized low-density lipoprotein, as well as AGEs-induced NF-κB activation and upregulation of proinflammatory gene expression. Moreover, expression of Il-10, an anti-inflammatory gene, was restored by this antagonist. These findings suggest that the RAGE-Diaph1 inhibitor could be a potential therapeutic drug against RAGE-related diseases, such as chronic inflammation and atherosclerosis.Entities:
Keywords: Advanced glycation end-products (AGEs); Cell signaling; Diaphanous related formin 1 (Diaph1); Oxidized low-density lipoprotein (oxLDL); RAGE-Diaph1 inhibitor; Receptor for advanced glycation end-products (RAGE)
Year: 2021 PMID: 33813279 DOI: 10.1016/j.bbrc.2021.03.139
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575